A poster presentation entitled, “Combining Epigenetic Chromatin Regulatory Elements, Cell Line Engineering and Cell Culture Condition Optimization in a Comprehensive Platform for Enhanced Recombinant Protein Production," will be presented by Dr. Gaussin.
Geneva, Switzerland (PRWEB) October 21, 2011
Selexis SA announced today data from the Company’s SUREtechnology Platform™ will be presented at the 2011 BioProcess International Conference and Exhibition, October 31 – November 4, 2011 at the Long Beach Convention Center in Long Beach, California.
A poster presentation entitled, “Combining Epigenetic Chromatin Regulatory Elements, Cell Line Engineering and Cell Culture Condition Optimization in a Comprehensive Platform for Enhanced Recombinant Protein Production,” is scheduled to be presented at booth number 39. The poster presentation will discuss new solutions for more efficient identification of individual therapeutic protein candidates. The company’s chief technology officer, Dr. Armelle Gaussin, will present the poster and will be available for questions on Wednesday, November 2, 2011 from 12:30 PM PST – 2:00 PM PST.
Full Poster Abstract:
The development of novel comprehensive mammalian expression platforms represents a growing need for advancing biopharmaceuticals towards human clinical trials. In an effort to address this issue, we have developed new solutions for more efficient identification of individual protein candidates in stably transfected CHO cells.
The combination of high transfection efficiency with the presence of epigenetic chromatin regulatory elements (Selexis Genetic Elements™) in the expression vectors results in higher efficiency of expression and stability of engineered cells. This allows improved vector integration, limited transgene silencing and higher transcription levels. Based on this approach, combinatorial human antibody libraries are generated in CHO cells to allow the identification of the most promising human antibody for both binding and expression.
However, additional bottlenecks linked to translation processes such as inefficient product processing and secretion remained to be addressed. Therefore, we developed SURE HTSchaperones™ based on metabolically engineered cells lines that co-express chaperones aiming at further increasing the protein yield. Notably, we reached 400% improvement with a difficult to express monoclonal antibody.
Furthermore, in order to improve the culture conditions of the Selexis SURE CHO-M Cell Line™, we developed the Selexis SUREfeed Strategy™ together with media optimization. As a result, a 4- to 7-fold increase in productivity could be achieved in combination with a T°C shift cultivation process.
Altogether, these approaches customized for each client project could support better clonal cell line performance in term of specific productivity, cell viability and product quality. This novel platform offers considerable time and labor savings as it enables the development of the production clonal cell line directly from the pool of transfectants in optimized culture conditions.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
For more information, visit http://www.selexis.com